Routine vaccination against MenB

Kaaijk, Patricia; Ende, Arie van der; Luytjes, Willem

doi:10.4161/hv.26816

Cited by 13 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first vaccine approved by the European Medicines Agency (EMA), developed by Novartis, has some protein most common circulating strains and potentially immunogenic, that expression on the bacterial surface [5]. Due to the high genetic variability of meningococcus B, was created a mathematical calculation Meningococcal Antigen Typing System (MATS) to estimate the percentage of circulating strains in a certain region [6].…”

Section: Discussionmentioning

confidence: 99%

“…Several clinical trials was held in children older than two months, teenagers and adults and in all age groups the vaccine proved to be immunogenic, safe and able to induce immunogenic memory, but this memory is not well defined [5][6][7][8][9][10]. The most common adverse effects of the vaccine are those related to the injection site, followed by nausea, headache, and fever with short and spontaneous cure.…”

Section: Discussionmentioning

confidence: 99%

“…There are variability of vaccines that act in the defense related to MD, and currently is used a few different types of vaccines all around the world. Europe has adopted only one of those, the 4CMenB (Bexero ® ), that is derived from bacterial proteins that stimulates the human immune system [2,3,5].…”

Section: General Medicine: Open Accessmentioning

confidence: 99%

See 2 more Smart Citations

Review and Recommendations of the Neisseria meningitidis Serogroup B Vaccine

Takara¹

2015

General Med

View full text Add to dashboard Cite

Background: Meningococcal disease (MD) has high incidence in children less than four years followed by teenagers and Young adults, with high mortality and comorbidities. Objectives: To review the recommendations of Neisseria meningitidis Serogroup B Vaccine around the world. Methods: Medical Literature non sitematic review in English and Portugues Languague in the last 20 years with the following MesH terms "Neisseria meningitidis Serogroup B Vaccine". Results: 16 papers were full read, of 20 selected. Article's origins of some recognized international relevant institutions like FDA, CDC and WHO. There is a consensus regarding the immunological security 4CMenB vaccine (Bexero ®). Discussion: The lack of knowledge of serogroup B strains circulating in Portugal and epidemiological data limits a real estimate to this situation in this country and is not possible to evaluate its benefit cost. European countries are in the middle and low ranges incidence of this MD. Conclusion: There is no consensus in different countries with similar epidemiology between each other and so with Portugal, on the cost-effectiveness relationship of introducing the vaccine for public funding. The specific studies in each region to evaluate the cost-effectiveness of the vaccine are necessary. Despite the lack of scientific evidence about the cost-effectiveness of vaccination, it is the only current way of prevention MD of serogroup B.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Review and Recommendations of the Neisseria meningitidis Serogroup B Vaccine

Takara¹

2015

General Med

View full text Add to dashboard Cite

show abstract

“…In Australia (2011), the incidence rate was 0.8/100,000 and in New Zealand (2012) was 1.2/100,000. 4 In 2009, 29 European countries have reported a meningococcal disease incidence of 0.92 cases per 100,000; the Republic of Ireland (3.4/100,000) and the UK (2.0/100,000) showed the highest rates. In 2011, MenB was responsible of 73.6% of reported cases, followed by serogroups C (14.4%) and Y (8.2%).…”

Section: Epidemiologymentioning

confidence: 99%

Meningococcal B vaccination: real-world experience and future perspectives

Kuhdari

Stefanati

Lupi

et al. 2016

Pathogens and Global Health

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) represents a severe risk for health. It can be considered the most dangerous vaccine-preventable disease due to the high probability of related permanent sequelae and death. The introduction in many countries of the conjugate vaccines against A, C, W135, and Y meningococcal serogroups influenced significantly the impact of the disease. Recently, the difficulties in obtaining an effective vaccine against meningococcal serogroup B (MenB) have been get over through the reverse vaccinology, enabling the recognition of some antigens providing a response against most of circulating MenB strains worldwide. The new 4cMenB vaccine is recommended in Europe, Canada, Australia, the USA, and some Latin American countries. Even if sound data on efficacy and safety profile are available, the results in terms of effectiveness are still limited. The management of the MenB outbreaks in two US universities demonstrated the ability to quickly achieve high vaccination coverage rates and no new cases among immunized subjects were assessed. It is desirable that the opportunity to complete preventive intervention against IMD offered by the new 4cMenB vaccine should be recognized and that this vaccine is included in the vaccination schedule to complete the panel of immunization against Neisseria meningitidis.

show abstract

“…MnB vaccination is not currently included in Canada's routine vaccination schedule but several provinces publicly fund the vaccine for recommended individuals at high risk of meningococcal disease. Adolescents and young adults are at highest risk of N. meningitidis carriage and transmission (Kaaijk et al 2014), so routine MnB vaccination in this population could help reduce the burden of IMD in Canada.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Breton

Huang

Snedecor

et al. 2020

Can J Public Health

View full text Add to dashboard Cite

Objective Serogroup B meningococci (MnB) are now the largest cause of invasive meningococcal disease (IMD) in Canada. We assessed the clinical and economic impact of 3 adolescent MenB-FHbp immunization strategies. Methods A population-based dynamic transmission model was developed to simulate the transmission of MnB among the entire Canadian population over a 30-year time horizon. Age group-based IMD incidence, bacterial carriage and transmission, disease outcomes, costs, and impact on quality of life were obtained from Canadian surveillance data and published literature. The vaccine was assumed to provide 85% protection against IMD and 26.6% against carriage acquisition. The model estimated the impact of routine vaccination with MenB-FHbp in 3 strategies: (1) age 14, along with existing school-based programs, with 75% uptake; (2) age 17 with 75% uptake, assuming school vaccination; and (3) age 17 with 30% uptake, assuming vaccination outside of school. Costs were calculated from the Canadian societal perspective. Results With no vaccination, an estimated 3974 MnB cases would be expected over 30 years. Vaccination with strategies 1-3 were estimated to avert 688, 1033, and 575 cases, respectively. These outcomes were associated with incremental costs per quality-adjusted life-year of $976,000, $685,000, and $490,000.Conclusions Our model indicated that if the vaccine reduces risk of carriage acquisition, vaccination of older adolescents, even at lower uptake, could have a significant public health impact. Due to low disease incidence, MnB vaccination is unlikely to meet widely accepted cost-effectiveness thresholds, but evaluations of new programs should consider the overall benefits of the vaccination. en milieu scolaire, à un taux de vaccination de 75 %; (2) immunisation à l'âge de 17 ans, en milieu scolaire, à un taux de vaccination de 75 %; et (3) immunisation à l'âge de 17 ans, à un taux de vaccination de 30 %, en contexte extrascolaire. Les coûts ont été calculés en fonction de la perspective sociétale canadienne. Résultats Sans immunisation, le nombre estimé de cas de méningococcie du sérogroupe B serait de 3974 sur une période de 30 ans. Selon le modèle, les stratégies de vaccination 1 à 3 préviendraient respectivement 688, 1033 et 575 cas. Ces résultats ont été associés à des coûts différentiels par année de vie gagnée ajustée par la qualité (QALY) de 976 000 $, 685 000 $ et 490 000 $. Conclusions Le modèle utilisé dans le cadre de l'analyse a permis d'indiquer que si le vaccin réduisait le risque d'acquisition du portage, la vaccination des adolescents plus vieux, même en présence de taux de vaccination plus faibles, pouvait avoir des répercussions significatives sur la santé publique. En raison de la faible incidence de la maladie, il est peu probable que la vaccination contre le MnB respecte les seuils généralement acceptés en matière de coût-efficacité, mais l'évaluation de nouveaux programmes devrait tenir compte de l'ensemble des bienfaits associés à la vaccination.

show abstract

Routine vaccination against MenB

Cited by 13 publications

References 36 publications

Review and Recommendations of the Neisseria meningitidis Serogroup B Vaccine

Review and Recommendations of the Neisseria meningitidis Serogroup B Vaccine

Meningococcal B vaccination: real-world experience and future perspectives

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Contact Info

Product

Resources

About